Navigation Links
Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
Date:12/21/2009

PRINCETON, N.J., Dec. 21 /PRNewswire-FirstCall/ -- Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today that it has initiated a Phase 1/2 clinical trial evaluating SGX201, a time-release formulation of oral beclomethasone 17,21-dipropionate (oral BDP), for the prevention of acute radiation enteritis. This study will be supported in large part by a two-year Small Business Innovation Research (SBIR) grant award, which will provide Soligenix with approximately $510,000 in funding.

The Phase 1/2 protocol BDP-ENT-01 is designed as a multicenter, open-label, sequential, dose-escalation study in approximately 36 patients. Patients with rectal cancer who are scheduled to undergo concurrent radiation and chemotherapy prior to surgery will be enrolled in one of four escalating dose groups. The objectives of the study are to evaluate the safety and maximal tolerated dose of escalating doses of SGX201, as well as the preliminary efficacy of SGX201 for prevention of signs and symptoms of acute radiation enteritis. The study is expected to be completed in the first half of 2011.

Acute radiation enteritis is an unmet medical need and caused by radiation-induced death of cells in the lining of the bowel. As bowel cells die and are not replaced, gastrointestinal toxicity develops over the next few days and weeks due to an inflammatory response to dead cells and bacteria, with chronic diarrhea, vomiting and pain being the major symptoms. The addition of chemotherapy often exacerbates the onset, severity and debilitation related to intestinal symptoms and itself can cause significant GI toxicity. This treatment-related enteritis often results in delay or interruption of the cancer treatment. There are over 100,000 patients annually in the United States who receive abdominal or pelvic external beam radiation treatment for cancer, and these pa
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014  El Camino Hospital, a ... care, is utilizing the Leaf Patient Monitoring system to ... and movement of patients susceptible to bed sores. ... month-long, 138-patient study of the system, which showed dramatic ... Turning patients regularly is the one of the most ...
(Date:7/30/2014)... , July 30, 2014  InnoPharma, Inc. today ... 10mg/vial (the generic equivalent of Zyprexa® injection), in Canada.  ... and disturbed behaviors in patients with schizophrenia or bipolar ... generic injectable drug, InnoPharma has entered into an agreement ... Canada will make, use, sell, market and distribute ...
(Date:7/30/2014)... Cynosure, Inc. (NASDAQ: CYNO ... non-invasive and minimally invasive applications, today announced that the Board ... and Chief Financial Officer Timothy W. Baker to ... will continue to serve as CFO and will take the ... Chairman and Chief Executive Officer. "Tim has ...
Breaking Medicine Technology:El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 2El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 3InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President 2
... ST. LOUIS, Dec. 21, 2010 Pepex Biomedical, ... solution for insulin dependent diabetics which will combine ... sufferers worldwide.  The company is developing a complete ... testing of blood glucose levels and insulin delivery, ...
... Reportlinker.com announces that a new market research report ... Cyclohexane: 2010 World Market Outlook And Forecast ... market research features all the important sides of ... focusing on the world market, regional and countries, ...
Cached Medicine Technology:Pepex™ Unveils Development of First All-In-One Blood Glucose Meter 2Reportlinker Adds Cyclohexane: 2010 World Market Outlook And Forecast 2
(Date:7/30/2014)... The family of a Vermont man ... Xarelto lawsuit ( http://www.xareltolawsuitcenter.com/ ) alleging his death ... reports. According to the complaint, which was filed in ... July 25th, the decedent had been taking Xarelto for ... bleed that ultimately led to his death on August ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Hamilton ... opening of its new Carmel office on July 30th. ... will finally be moving to the state-of-the-art suite, located ... and innovative space will allow for one-on-one patient comfort, ... surgery experience. , Dr. Hamilton’s new office-suite will ...
(Date:7/30/2014)... 2014 DRE Medical — a leading ... launch of its Medical Trade Shows & Conventions ... professionals and equipment vendors. , The calendar is a ... the United States and around the world. Hundreds of ... number is always growing. , Information listed on each ...
(Date:7/30/2014)... The Technology Association of Georgia in ... (B&TA), today issued its final call for applications and ... companies have until August 29th 2014 to be considered ... selected by the Excalibur Judging Committee. Companies selected as ... judges for interviewing process. , The TAG Excalibur ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 LTC Consumer, an ... long term care insurance, features an Instant Quote tool on ... and co-founder of LTC Consumer. Quotes are free and unlimited. ... click in only seven areas – including age, gender, and ... screen within seconds (you don’t need to enter any contact ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2Health News:DRE Launches Online Interactive Medical Trade Show Calendar 2Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 2Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 3Health News:LTC Consumer Launches Online Tool for Getting Instant Long Term Care Insurance Estimates 2
... acclaimed as the "gold-standard" amongst researchers for scientific studies. ... on the other, has also questioned the worth of ... complementary and alternative medicine (CAM) practices. Majority of CAM ... cure. , ,The question arises as to whether ...
... Diabetes is the leading cause of end-stage kidney disease ... or a kidney transplant for survival. // ,A ... and the University of Heidelberg has proven that a ... kidney failure or "end-stage renal disease." ,The ...
... are facing one of the worst gastroenteritis epidemics that ... with patients coming// in droves for relief. The infection ... for a few days but seldom endangers life. ... Montreal area have reported the viral outbreak. Dr. Joseph ...
... have been created from blue green algae by scientists with ... on properties and actions of enzymes is also taken into ... possible to produce enough of the promising drugs for use ... the cover of the January issue of the journal ACS ...
... recent studies have shown that the chance of developing it ... the chances of surviving it, also depend on the same ... 50,000 pounds behind a study to be carried out by ... cancer survivors aged above fifty and with a BMI (Body ...
... detect infection of drug resistant forms of HIV even when ... the Duke University Medical Center. ,This new test ... in small amounts contrary to other tests that detect drug-resistant ... bloodstream. ,This new test is expected to be ...
Cached Medicine News:Health News:Is Evidence-based Medicine Enough to Support Additional Research in Alternative Medicine? 2Health News:A Gene Associated With Severe Kidney Failure in Diabetes Found 2Health News:Anti Cancer Drug from Blue Green Algae 2
... Enzyme-linked immunosorbent assay method for ... autoantibodies to myeloperoxidase in human serum. ... can be used as an aid ... and other conditions associated with elevated ...
... of this Enzyme ImmunoAssay (EIA) is as ... immobilised on a 96 well microtiter plate. ... washing, the trapped molecule is covalently linked ... groups. After washing and denaturing treatment, Angiotensin ...
... determination of Ang II is ... the pharmacological effect and efficiency ... angiotensin converting enzyme inhibitors (ACE ... antagonists as well as for ...
Anti-RSV IgA Assay (ELISA)....
Medicine Products: